304 related articles for article (PubMed ID: 21901278)
1. Development of vaccine delivery vehicles based on lactic acid bacteria.
Tarahomjoo S
Mol Biotechnol; 2012 Jun; 51(2):183-99. PubMed ID: 21901278
[TBL] [Abstract][Full Text] [Related]
2. Mucosal vaccination and therapy with genetically modified lactic acid bacteria.
Wells J
Annu Rev Food Sci Technol; 2011; 2():423-45. PubMed ID: 22129390
[TBL] [Abstract][Full Text] [Related]
3. Recombinant lactic acid bacteria as delivery vectors of heterologous antigens: the future of vaccination?
Trombert A
Benef Microbes; 2015; 6(3):313-24. PubMed ID: 25245573
[TBL] [Abstract][Full Text] [Related]
4. Salmonella enterica as a vaccine carrier.
Hegazy WA; Hensel M
Future Microbiol; 2012 Jan; 7(1):111-27. PubMed ID: 22191450
[TBL] [Abstract][Full Text] [Related]
5. Lactic acid bacteria as live vaccines.
Mercenier A; Müller-Alouf H; Grangette C
Curr Issues Mol Biol; 2000 Jan; 2(1):17-25. PubMed ID: 11464916
[TBL] [Abstract][Full Text] [Related]
6. Cytoplasmic expression of a model antigen with M Cell-Targeting moiety in lactic acid bacteria and implication of the mechanism as a mucosal vaccine via oral route.
Oh SH; Kim SH; Jeon JH; Kim EB; Lee NK; Beck S; Choi YJ; Kang SK
Vaccine; 2021 Jul; 39(30):4072-4081. PubMed ID: 34127296
[TBL] [Abstract][Full Text] [Related]
7. Lactic acid bacteria - promising vaccine vectors: possibilities, limitations, doubts.
Szatraj K; Szczepankowska AK; Chmielewska-Jeznach M
J Appl Microbiol; 2017 Aug; 123(2):325-339. PubMed ID: 28295939
[TBL] [Abstract][Full Text] [Related]
8. Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health.
Levit R; Cortes-Perez NG; de Moreno de Leblanc A; Loiseau J; Aucouturier A; Langella P; LeBlanc JG; Bermúdez-Humarán LG
Gut Microbes; 2022; 14(1):2110821. PubMed ID: 35960855
[TBL] [Abstract][Full Text] [Related]
9. Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option.
Wang M; Gao Z; Zhang Y; Pan L
Appl Microbiol Biotechnol; 2016 Jul; 100(13):5691-701. PubMed ID: 27154346
[TBL] [Abstract][Full Text] [Related]
10. [Advances in the use of lactic acid bacteria as mucosal delivery vectors of therapeutic molecules].
Zeng Z
Sheng Wu Gong Cheng Xue Bao; 2021 Jul; 37(7):2272-2282. PubMed ID: 34327894
[TBL] [Abstract][Full Text] [Related]
11. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria.
van Roosmalen ML; Kanninga R; El Khattabi M; Neef J; Audouy S; Bosma T; Kuipers A; Post E; Steen A; Kok J; Buist G; Kuipers OP; Robillard G; Leenhouts K
Methods; 2006 Feb; 38(2):144-9. PubMed ID: 16414272
[TBL] [Abstract][Full Text] [Related]
12. Lactic acid bacteria--20 years exploring their potential as live vectors for mucosal vaccination.
Wyszyńska A; Kobierecka P; Bardowski J; Jagusztyn-Krynicka EK
Appl Microbiol Biotechnol; 2015 Apr; 99(7):2967-77. PubMed ID: 25750046
[TBL] [Abstract][Full Text] [Related]
13. Live bacterial vaccines--a review and identification of potential hazards.
Detmer A; Glenting J
Microb Cell Fact; 2006 Jun; 5():23. PubMed ID: 16796731
[TBL] [Abstract][Full Text] [Related]
14. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
De Magistris MT
Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
[TBL] [Abstract][Full Text] [Related]
15. Combined use of lactic-acid-producing bacteria as probiotics and rotavirus vaccine candidates expressing virus-specific proteins.
Afchangi A; Latifi T; Jalilvand S; Marashi SM; Shoja Z
Arch Virol; 2021 Apr; 166(4):995-1006. PubMed ID: 33533975
[TBL] [Abstract][Full Text] [Related]
16. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum.
Grangette C; Müller-Alouf H; Goudercourt D; Geoffroy MC; Turneer M; Mercenier A
Infect Immun; 2001 Mar; 69(3):1547-53. PubMed ID: 11179325
[TBL] [Abstract][Full Text] [Related]
17. Current issues regarding the application of recombinant lactic acid bacteria to mucosal vaccine carriers.
Takahashi K; Orito N; Tokunoh N; Inoue N
Appl Microbiol Biotechnol; 2019 Aug; 103(15):5947-5955. PubMed ID: 31175431
[TBL] [Abstract][Full Text] [Related]
18. Oral vaccine delivery by recombinant spore probiotics.
Cutting SM; Hong HA; Baccigalupi L; Ricca E
Int Rev Immunol; 2009; 28(6):487-505. PubMed ID: 19954360
[TBL] [Abstract][Full Text] [Related]
19. Bioadhesive delivery systems for mucosal vaccine delivery.
Baudner BC; O'Hagan DT
J Drug Target; 2010 Dec; 18(10):752-70. PubMed ID: 21039314
[TBL] [Abstract][Full Text] [Related]
20. Animal vaccines based on orally presented yeast recombinants.
Shin MK; Yoo HS
Vaccine; 2013 Sep; 31(40):4287-92. PubMed ID: 23891501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
